ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2025
Targeting triple-negative breast cancer: apoptotic and antitumor effects of Artemisia sieberi Besser extracts.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chemical Profiling and ROS-Dependent Antiproliferative Activity of Artemisia nilagirica (C.B.Clarke) Pamp. (Asteraceae) Essential Oil in Human Gastric Adenocarcinoma Cells.Chemistry & biodiversity · 2026Article
- Design, optimization and characterization of mucoadhesive buccal film as a novel delivery system for doxazosin mesylate.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Artemisia sieberi Besser (A. sieberi) has shown promise as a natural source of safe cytotoxic agents for breast cancer therapy. However, its effects on triple-negative breast cancer (TNBC), a very aggressive subtype lacking targeted treatments, remain poorly studied. This study evaluates the anticancer activity of A. sieberi extracts against the MDA-MB-231 TNBC cell line, comparing results with hormone receptor-positive MCF-7 cells. Aerial parts of A. sieberi were extracted using ethanol and methanol and then chemically characterized via gas chromatography/mass spectrometry (GC/MS) to identify bioactive compounds. Cytotoxic effects were assessed using cell viability assays, while apoptosis induction was examined through flow cytometry (Annexin V/propidium iodide staining), caspase-3/-7 activation assays, and mitochondrial membrane permeabilization visualized using confocal microscopy. Western blotting analyzed the expression levels of apoptotic proteins. In silico molecular docking simulations explored the interactions between phytochemicals and apoptosis-regulating proteins. A. sieberi extracts exhibited higher cytotoxicity against MDA-MB-231 cells than against MCF-7 cells, with lower IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.